Page last updated: 2024-08-26

nicotine and fluvoxamine

nicotine has been researched along with fluvoxamine in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's6 (60.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Dansette, PM; Fontana, E; Poli, SM1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Gunosewoyo, H; Kozikowski, AP; Yu, LF; Zhang, HK1
Kuhlman, G; Mosner, A; Roehm, C; Vogel, WH1
Kurasawa, M; Nakamura, K1
Bubl, B; Feuerstein, TJ; Hubbe, U; Huethe, F; Jackisch, R; Löffler, M; McIntosh, JM1
Izumi, T; Ohmura, Y; Tsutsui-Kimura, I; Yamaguchi, T; Yoshida, T; Yoshioka, M1

Reviews

1 review(s) available for nicotine and fluvoxamine

ArticleYear
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
    Current drug metabolism, 2005, Volume: 6, Issue:5

    Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic

2005

Other Studies

9 other study(ies) available for nicotine and fluvoxamine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.
    ACS medicinal chemistry letters, 2012, Dec-13, Volume: 3, Issue:12

    Topics:

2012
Serotonergic receptors modify the voluntary intake of alcohol and morphine but not of cocaine and nicotine by rats.
    Pharmacology, 1997, Volume: 54, Issue:4

    Topics: Alcohol Drinking; Animals; Choice Behavior; Cocaine; Fluvoxamine; Male; Morphine; Narcotics; Nicotine; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists

1997
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
    European journal of pharmacology, 2001, May-18, Volume: 420, Issue:1

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bromocriptine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Fear; Fluvoxamine; Haloperidol; Indophenol; Male; Maze Learning; Mecamylamine; Mice; Mice, Inbred ICR; Moclobemide; Motor Activity; Nicotine; Nicotinic Antagonists; Nortriptyline; Physostigmine; Picolinic Acids; Pyrrolidinones; Serotonin Antagonists; Serotonin Receptor Agonists; Social Behavior; Stress, Psychological

2001
Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release.
    Brain research bulletin, 2006, Jan-30, Volume: 68, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adolescent; Adult; Aged; Alkaloids; Analysis of Variance; Animals; Autoreceptors; Azocines; Calcium; Child; Child, Preschool; Domperidone; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Feedback; Female; Fluvoxamine; Humans; In Vitro Techniques; Isoxazoles; Male; Maprotiline; Mice; Middle Aged; Neocortex; Nicotine; Nicotinic Antagonists; Potassium; Pyrrolidines; Quinolizines; Rats; Receptors, Nicotinic; Sulpiride; Time Factors; Tritium

2006
The effects of serotonin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats.
    Behavioural pharmacology, 2009, Volume: 20, Issue:5-6

    Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Behavior, Animal; Choice Behavior; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fluvoxamine; Impulsive Behavior; Male; Milnacipran; Nicotine; Nicotinic Agonists; Propylamines; Rats; Rats, Wistar; Reaction Time; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors

2009